What DSIP is
Delta sleep-inducing peptide, usually shortened to DSIP, is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of 848.81 Da (CAS 62568-57-4). The Schoenenberger-Monnier research group in Basel isolated it in 1977 from the cerebral venous blood of rabbits after low-frequency electrical stimulation of the intralaminar thalamic nuclei, a stimulation pattern known to produce delta-wave EEG activity associated with slow-wave sleep (Schoenenberger and Monnier, PNAS, 1977).
The name comes from that original EEG association, not from a confirmed sleep-promoting mechanism. Nearly fifty years later, no gene, precursor protein, or receptor for DSIP has been identified. A 2006 review in the Journal of Neurochemistry called the compound "a still unresolved riddle," noting that the link between DSIP and sleep has never been mechanistically confirmed (Kovalzon and Strekalova, J Neurochem, 2006). That unresolved status has not changed since.
Endogenous DSIP-like immunoreactivity turns up in more places than the brain. Published measurements report it in plasma at roughly 0.4 to 1.0 pmol/mL, in cerebrospinal fluid, in the pituitary gland, and in the gastrointestinal tract, alongside multiple brain regions. That wide tissue distribution is part of why a single receptor has been difficult to pin down: a peptide detected in that many compartments could plausibly act through more than one binding site, or through none at all if some of what immunoassays detect is a larger carrier-bound form rather than free peptide.
Mechanism: what the animal research shows
The clearest mechanistic data on DSIP comes from rat studies of growth hormone release. Iyer and McCann injected 5 mcg of DSIP into the third cerebral ventricle of ovariectomized rats and measured a significant rise in plasma growth hormone by 30 minutes, sustained through the 120-minute study window. The effect was dose-related down to a minimal effective dose of 0.1 mcg, and pretreatment with pimozide, a dopamine receptor blocker, blocked it, pointing to a hypothalamic dopaminergic pathway. Dispersed pituitary cells from the same animals also released more growth hormone when exposed to DSIP directly, so the peptide appears to act at both the hypothalamus and the pituitary (Iyer and McCann, Peptides, 1987, rat model).
The same research group traced part of the mechanism behind that growth hormone rise. Somatostatin normally suppresses growth hormone secretion from the pituitary, and Iyer and McCann showed in a separate in vitro incubation of rat hypothalamic median eminence tissue that DSIP inhibited somatostatin release in a dose-dependent way. Pimozide blocked this effect too, at a concentration of 10-6 M, while pimozide alone did nothing to somatostatin release on its own (Iyer and McCann, Neuroendocrinology, 1987, rat median eminence). Less somatostatin reaching the pituitary is one plausible route to more growth hormone reaching circulation, and it lines up with the dopaminergic pathway identified in the intraventricular experiment.
Work on the hypothalamic-pituitary-adrenal axis has produced conflicting results in humans. Bjartell and colleagues gave synthetic DSIP intravenously to 11 healthy men in a randomized, double-blind crossover design and found a significant drop in plasma immunoreactive ACTH that lasted at least 3 hours (Bjartell et al., Psychoneuroendocrinology, 1989, n=11). A later study by Spath-Schwalbe and colleagues tested whether DSIP could blunt the ACTH and cortisol response to corticotropin-releasing hormone infusion or to a midday meal in 10 healthy young men, and found no effect on either (Spath-Schwalbe et al., Psychoneuroendocrinology, 1995, n=10).
The two studies measured different things, baseline secretion versus a stimulated response, so the discrepancy is not a direct contradiction. It does mean DSIP's effect on the HPA axis in humans remains unsettled.
What the human sleep trials found
The earliest human sleep data comes from an open, uncontrolled trial. Kaeser treated 7 patients with severe insomnia using a series of 10 DSIP injections; sleep normalized in 6 of the 7 cases, with the improvement holding for 3 to 7 months of follow-up (Kaeser, European Neurology, 1984, n=7). Open trials without a placebo arm are prone to expectation effects, and this one carries that limitation.
The stronger evidence comes from Bes and colleagues, who ran a double-blind, matched-pairs, parallel-groups trial in 16 chronic insomnia patients comparing DSIP to placebo. Objective sleep recordings showed higher sleep efficiency and shorter sleep latency with DSIP, but the authors flagged the effects as weak and possibly confounded by an unrelated shift in the placebo group's sleep during the study (Bes et al., Neuropsychobiology, 1992, n=16). Researchers questioning their own positive result is uncommon, and it is worth weighing alongside the headline finding rather than instead of it.
Stability and handling
DSIP degrades quickly once it reaches circulation. Graf, Saegesser, and Schoenenberger incubated DSIP in human and rat blood and found rapid cleavage of the N-terminal tryptophan residue, consistent with aminopeptidase activity. A phosphorylated analog degraded more slowly but instead formed complexes with plasma proteins (Graf et al., Peptides, 1987). Reported plasma half-life estimates for unmodified DSIP cluster around 7 to 15 minutes depending on the assay, short relative to most research peptides sold as longer-acting analogs.
None of that changes the storage rules for the lyophilized powder before use. Keep it frozen and desiccated until reconstitution, and follow the same aseptic technique used for any other research peptide, covered step by step in the reconstitution guide. Bali and other parts of Indonesia run humid enough, often above 70% relative humidity, that lyophilized powder left outside a sealed, desiccated container picks up moisture faster than it would in a temperate lab.
General storage rules for that climate are covered in the peptide storage guide. Once reconstituted, keep the solution refrigerated and use the dosing calculator to check volume draws against the stated concentration.
How DSIP compares to Semax and Selank
Vendor catalogs often group DSIP with Semax and Selank under a loose "sleep and stress" category, but the research lineages do not overlap. Semax and Selank came out of Russian Academy of Sciences groups working on ACTH fragments and tuftsin derivatives. DSIP came out of a Swiss group in Basel studying thalamic stimulation and EEG patterns.
The mechanisms differ just as much: Semax works through melanocortin receptors, Selank works through GABAergic and BDNF-linked pathways, and DSIP has no identified receptor at all. Grouping the three by marketing category is convenient, but treating them as mechanistically related would be incorrect. Full mechanism and trial detail on the Russian-derived compounds is in the Semax compound listing.
Evidence summary and research limitations
DSIP's animal pharmacology is fairly consistent: intraventricular and direct pituitary administration reliably raises growth hormone in rats through a dopamine-dependent pathway. Its human data is smaller and split. One double-blind study found a reduction in plasma ACTH; another double-blind study using a stronger HPA stimulus found no effect. The best-controlled sleep trial found a statistically positive but weak result that its own authors questioned.
That basic biology is still missing after almost 50 years of published research, which is unusual for a peptide this studied. No Phase 2 or Phase 3 trial appears on ClinicalTrials.gov, and neither the FDA nor the EMA has evaluated DSIP for any indication. Researchers should treat DSIP as a compound with solid rodent growth hormone data, contradictory human HPA axis data, and sleep evidence too thin and too mixed to draw firm conclusions from.